Accelerate Diagnostics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 0/6

Accelerate Diagnostics şirketinin toplam hissedar öz sermayesi $-48.5M ve toplam borcu $58.0M olup, bu da borç-öz sermaye oranını -119.6% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $32.3M ve $80.8M dir.

Anahtar bilgiler

-119.6%

Borç/özkaynak oranı

US$58.01m

Borç

Faiz karşılama oranı	n/a
Nakit	US$20.91m
Eşitlik	-US$48.48m
Toplam yükümlülükler	US$80.80m
Toplam varlıklar	US$32.32m

Son finansal sağlık güncellemeleri

Recent updates

Market Participants Recognise Accelerate Diagnostics, Inc.'s (NASDAQ:AXDX) Revenues Pushing Shares 38% Higher

Apr 17

Accelerate Diagnostics spikes as Chief Technology Officer raises stake

Aug 30

Need To Know: Analysts Are Much More Bullish On Accelerate Diagnostics, Inc. (NASDAQ:AXDX)

Aug 20

Accelerate Diagnostics jumps 14% after beating Q2 estimates

Aug 15

Need To Know: The Consensus Just Cut Its Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Estimates For 2022

Mar 15

Accelerate Diagnostics And T2 Biosystems: Financial Woes Set To Continue In 2022

Jan 04

Accelerate Diagnostics: An Investment Assessment

Sep 07

Should You Take Comfort From Insider Transactions At Accelerate Diagnostics, Inc. (NASDAQ:AXDX)?

Feb 20

Accelerate Diagnostics foresees Q4 and FY2020 revenue below consensus

Jan 12

Reflecting on Accelerate Diagnostics' (NASDAQ:AXDX) Share Price Returns Over The Last Three Years

Dec 29

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: AXDX negatif hissedar özkaynağı var; bu, kısa vadeli varlıkların kısa vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Uzun Vadeli Yükümlülükler: AXDX şirketinin negatif özkaynağı bulunmaktadır; bu, kısa vadeli varlıkların uzun vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: AXDX negatif hissedar özkaynağı var ki bu yüksek borç seviyesinden daha ciddi bir durumdur.

Borcun Azaltılması: AXDX 'in negatif özkaynağı var, dolayısıyla borcunun zaman içinde azalıp azalmadığını kontrol etmemize gerek yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: AXDX şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: Serbest nakit akışı her yıl % 11.2 oranında tarihsel oranda büyümeye devam ederse AXDX un bir yıldan az nakit akışı süresi vardır.

Accelerate Diagnostics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 0/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Accelerate Diagnostics, Inc. Receives Written Notice from the Listing Qualifications Staff of Nasdaq

Accelerate Diagnostics, Inc. Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC

Accelerate Diagnostics Announces 1-For-10 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of $1.00 Per Share Required to Maintain Continued Listing on the Nasdaq Capital Market

Accelerate Diagnostics Receives A Deficiency Letter from Nasdaq Regarding Minimum Bid Price Requirement

Recent updates

Accelerate Diagnostics, Inc. Announces FDA Clearance of its Accelerate Arc™? System

Accelerate Diagnostics, Inc. Announces Successful Completion of Its Wave Pre-Clinical Trial

Accelerate Diagnostics, Inc. to Report Q1, 2024 Results on May 08, 2024

Accelerate Diagnostics, Inc. Receives Written Notice from the Listing Qualifications Staff of Nasdaq

Accelerate Diagnostics, Inc., Annual General Meeting, May 07, 2024

Accelerate Diagnostics, Inc. Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC

Accelerate Diagnostics, Inc. announced that it expects to receive $4.749996 million in funding from Jack W. Schuler Living Trust

Accelerate Diagnostics, Inc. has completed a Composite Units Offering.

Accelerate Diagnostics Announces 1-For-10 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of $1.00 Per Share Required to Maintain Continued Listing on the Nasdaq Capital Market

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 15%

Market Participants Recognise Accelerate Diagnostics, Inc.'s (NASDAQ:AXDX) Revenues Pushing Shares 38% Higher

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

CEO, President & Director exercised options and sold US$73k worth of stock

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Accelerate Diagnostics Receives A Deficiency Letter from Nasdaq Regarding Minimum Bid Price Requirement

Accelerate Diagnostics Submits 510(K) Application to FDA for Gram-Negative Menu Expansion and Breakpoint Updates for the Accelerate Phenotest(R) BC Kit

Accelerate Diagnostics, Inc. Announces Resignation of Ron Price as Chief Commercial Officer

Consensus forecasts updated

Price target decreased to US$2.00

Accelerate Diagnostics, Inc. Provides Earnings Guidance for the Year 2022

Insider recently bought US$80k worth of stock

Accelerate Diagnostics spikes as Chief Technology Officer raises stake

Consensus revenue estimates increase by 10%

Need To Know: Analysts Are Much More Bullish On Accelerate Diagnostics, Inc. (NASDAQ:AXDX)

Accelerate Diagnostics, Inc. has completed a Follow-on Equity Offering in the amount of $35 million.

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Accelerate Diagnostics jumps 14% after beating Q2 estimates

CEO, President & Director exercised options and sold US$26k worth of stock

Consensus forecasts updated

Accelerate Diagnostics Announces Commercialization of its Accelerate Arc System Having Completed IVD Registration with FDA

First quarter 2022 earnings: EPS exceeds analyst expectations

CEO, President & Director exercised options and sold US$82k worth of stock

Price target decreased to US$5.00

Accelerate Diagnostics, Inc., Annual General Meeting, May 12, 2022

Accelerate Diagnostics, Inc. Announces Launch of Accelerate Arc™ Module and BC Kit

Need To Know: The Consensus Just Cut Its Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Estimates For 2022

Consensus revenue estimates fall by 14%

Full year 2021 earnings: EPS exceeds analyst expectations

Accelerate Diagnostics, Inc. Elects Wayne C. Burris as Member of the Board

Insider recently bought US$66k worth of stock

Independent Director recently bought US$524k worth of stock

Independent Director recently bought US$196k worth of stock

Accelerate Diagnostics, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2021

Independent Director recently bought US$277k worth of stock

Accelerate Diagnostics And T2 Biosystems: Financial Woes Set To Continue In 2022

Independent Director recently bought US$369k worth of stock

Independent Director recently bought US$248k worth of stock

Independent Director recently bought US$606k worth of stock

Accelerate Diagnostics, Inc. Announces New Accelerate Pheno System Multi-Center Study Published in Clinical Infectious Diseases

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.33 loss in 3Q 2020)

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.33 loss in 3Q 2020)

Accelerate Diagnostics, Inc. announced that it has received $1.55 million in funding

Independent Director recently bought US$150k worth of stock

Price target decreased to US$11.00

Accelerate Diagnostics: An Investment Assessment

Second quarter 2021 earnings released: US$0.35 loss per share (vs US$0.35 loss in 2Q 2020)

Consensus forecasts updated

Accelerate Diagnostics, Inc. to present New Accelerate Pheno® Landmark Study Validates Important Clinical Benefits at ECCMID 2021

CEO, President & Director exercised options and sold US$186k worth of stock

Key Executive exercised options and sold US$56k worth of stock

Price target decreased to US$11.00

First quarter 2021 earnings released: US$0.41 loss per share (vs US$0.39 loss in 1Q 2020)

Accelerate Diagnostics, Inc. Announces Roland D. Diggelmann Decision Not to Stand for Re-Election to Its Board

Analysts lower revenue estimates to US$16.5m

Earnings beat expectations, revenue disappoints

Full year 2020 earnings released: US$1.40 loss per share (vs US$1.55 loss in FY 2019)

Should You Take Comfort From Insider Transactions At Accelerate Diagnostics, Inc. (NASDAQ:AXDX)?

Key Executive exercised options and sold US$701k worth of stock

New 90-day high: US$12.96